Alvotech, a biotech company, has successfully placed $108 million in senior unsecured convertible bonds due 2030 to support R&D investment and global product launches. The oversubscribed offering will help the company advance its pipeline, scale production capacity, and support new product launches. The bonds carry a coupon of 6.875% and are convertible into Swedish Depositary Receipts. Alvotech is focused on developing biosimilar medicines, with a robust pipeline of 30 products and strategic partnerships for global reach. The company aims to deliver high-quality, cost-effective treatments to patients worldwide. This press release contains important information regarding the offering and placement of the convertible bonds.

Read more at GlobeNewswire: Alvotech Successfully Places USD 108 Million Senior